| Literature DB >> 31874870 |
Lin Zhang1,2,3,4, Huachun Zou5,6, Yang Zhao7,8, Chunlei Hu9, Adejare Atanda10, Xuzhen Qin1, Peng Jia11,12, Yu Jiang13, Zhihong Qi14.
Abstract
OBJECTIVES: To assess the association between blood circulating vitamin D levels and colorectal cancer risk in the Asian population.Entities:
Keywords: 25-hydroxyvitamin D; Asia; colorectal adenoma; colorectal cancer; meta-analysis; vitamin D
Year: 2019 PMID: 31874870 PMCID: PMC7008426 DOI: 10.1136/bmjopen-2019-030513
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram of study selection for meta-analysis.
Figure 2Meta-analysis of association between blood circulating vitamin D and the risk of colorectal cancer. The adjusted ORs of colorectal cancer for the highest versus lowest categories of blood vitamin D level from each study were included. The size of each square is proportional to the weight of the study. The range is the difference in the midpoint between the highest and lowest categories of blood vitamin D.
Figure 3Dose-response relationship between blood vitamin D levels and the ORs of colorectal cancer. Adjusted OR and 95% CIs (dashed lines) are reported. Blood vitamin D levels were modelled with a linear and spline model in a random-effects meta-regression model. The median value of the lowest reference interval (3.65 ng/mL) was used to estimate all ORs. The vertical axis is on a log scale. Lines with long dashes represent the pointwise 95% CIs for the fitted spline model with a non-linear trend (solid line, P non-linearity=0.11). Lines with short dashes represent the linear trend.
Summary of subgroup analysis for the associations of blood circulating vitamin D and the risk of colorectal cancer and adenoma by outcome, sex, the subregion of Asia, blood sample type and range.
| Subgroup analysis | Number of estimates | Random effect | Ratio of ORs (95% CI) |
| P value* |
| Outcome | |||||
| Colorectal adenoma | 4 | 0.67 (0.40 to 1.14) | |||
| Colorectal cancer | 4 | 0.83 (0.66 to 1.06) | 1.11 (0.54 to 2.28) | 59.48 | 0.73 |
| Sex | |||||
| Women | 2 | 0.59 (0.13 to 2.74) | |||
| Men | 3 | 1.13 (0.81 to 1.58) | 1.46 (0.03 to 63.5) | 45.89 | 0.70 |
| Subregion | |||||
| Eastern Asia | 7 | 0.75 (0.57 to 1.00) | |||
| Western Asia | 1 | 0.69 (0.36 to 1.34) | 0.92 (0.28 to 2.99) | 59.79 | 0.87 |
| Blood sample type | |||||
| Serum | 3 | 0.52 (0.34 to 0.80) | |||
| Plasma | 4 | 0.77 (0.59 to 1.00) | 1.49 (0.73 to 3.03) | 22.67 | 0.21 |
| Range | |||||
| ≤15 ng/mL | 4 | 0.93 (0.70 to 1.25) | |||
| >15 ng/mL | 4 | 0.62 (0.47 to 0.83) | 0.65 (0.39 to 1.07) | 28.48 | 0.08 |
*I2 and p value related to subgroup differences.
I2, per cent residual variation due to heterogeneity.
Summary of characteristics for eight studies included in the meta-analysis
| Author (year) | Study design | Country | Study period | Outcome | Outcome ascertainment | Sex | Sample size (n); characteristics | Blood sample type | Vitamin D testing method | |||
| Case or control | No. | Male (%) | Mean age (SD)/median age (range) | |||||||||
| Budhathoki | Nested case-cohort | Japan | 1990–2009 | Colorectal cancer | NA | All* | Case | 637 | 52 | 56.2 (7.5) | Plasma | Chemiluminescent enzyme immunoassay |
| Control | 4044 | 34 | 53.7 (7.9) | |||||||||
| Choi | Case-control | Korea | 2011–2012 | Colorectal adenoma | Colonoscopy | All | Case | 112 | 51 | 60.3 (5.3) | Serum | Chemiluminescent enzyme immunoassay |
| Control | 112 | 51 | 59.5 (5.4) | |||||||||
| Men | Case | 57 | 100 | NA | Serum | |||||||
| Control | 57 | 100 | NA | |||||||||
| Women | Case | 55 | 0 | NA | Serum | |||||||
| Control | 55 | 0 | NA | |||||||||
| Hong | Case-control | Korea | 2009–2010 | Colorectal adenoma | Colonoscopy | All | Case | 143 | 68 | 58.7 (6.0) | Serum | Direct competitive electrochemiluminescence immunoassay |
| Control | 143 | 68 | 58.7 (6.0) | |||||||||
| Otani | Case-control | Japan | 1990–2003 | Colorectal cancer | Pathologically confirmed | All | Case | 323 | 52 | NA | Plasma | Competitive protein-binding assay |
| Control | 621 | 52 | NA | |||||||||
| Men | Case | 163 | 100 | 56.9 | ||||||||
| Control | 324 | 100 | 56.9 | |||||||||
| Women | Case | 160 | 0 | 56.5 | ||||||||
| Control | 297 | 0 | 56.4 | |||||||||
| Takahashi | Case-control | Japan | 1997–2004 | Colorectal adenoma | Colonoscopy | Men | Case | 656 | 100 | 52.0 (1.4) | Plasma or Serum | Radioimmunoassay method |
| Control | 648 | 100 | 51.8 (1.5) | |||||||||
| Yamaji | Case-control | Japan | 2004–2005 | Colorectal adenoma | Colonoscopy | All | Case | 737 | 67 | NA | Plasma | Radioimmunoassay method |
| Control | 703 | 65 | NA | |||||||||
| Ying | Case-control | China | 2010–2014 | Colorectal cancer | Colonoscopy | All | Case | 212 | NA | 63(56-73) | Plasma | Direct competitive ELISA |
| Control | 212 | NA | 63(57-73) | |||||||||
| Yurekli | Case-control | Turkey | 2012 | Colorectal cancer | Colonoscopy | All | Cases | 96 | 67 | 57.8 (10.0) | Serum | NA |
| control | 195 | 54 | 51.2 (12.9) | |||||||||
All*: all participants, including men and women
NA, not available; SD, standard deviation.
Summary of risk estimates for eight studies included in the meta-analysis
| Author (year) | Sex | Vitamin D level cut points | Vitamin D medium level | Number of cases | Number of controls | N | OR | LCI | UCI | Adjusted variables |
| Budhathoki | All* | First Q, 12.5–16.5 ng/mL | 14.7 | 134 | 1004 | 1138 | 1 | Age, sex, BMI, smoking, alcohol use, physical activity, family history of cancer and history of diabetes | ||
| Second Q, 17.6–21.6 ng/mL | 19.9 | 165 | 1000 | 1165 | 1.08 | 0.84 | 1.39 | |||
| Third Q, 21.2–25.6 ng/mL | 21.3 | 160 | 1016 | 1176 | 0.96 | 0.74 | 1.26 | |||
| Fourth Q, 25.8–33.0 ng/mL | 26.5 | 178 | 1024 | 1202 | 0.95 | 0.73 | 1.23 | |||
| Choi | All | First Q, 10.3 ng/mL | 10.3 | 37 | 28 | 65 | 1 | Age, sex, BMI, alcohol drinking, smoking status, folate intake; women: additional menopausal status and hormone replacement use | ||
| Second Q, 14.3 ng/mL | 14.3 | 26 | 28 | 54 | 0.72 | 0.31 | 1.66 | |||
| Third Q, 17.9 ng/mL | 17.9 | 28 | 28 | 56 | 0.73 | 0.29 | 1.82 | |||
| Fourth Q, 24.2 ng/mL | 24.2 | 21 | 28 | 49 | 0.49 | 0.19 | 1.27 | |||
| Men | First Q, 11.1 ng/mL | 11.1 | 15 | 14 | 29 | 1 | ||||
| Second Q, 14.6 ng/mL | 14.6 | 13 | 14 | 27 | 1.31 | 0.36 | 4.82 | |||
| Third Q, 17.7 ng/mL | 17.7 | 17 | 15 | 32 | 1.26 | 0.4 | 8.12 | |||
| Fourth Q, 22.7 ng/mL | 22.7 | 12 | 14 | 26 | 1.8 | 0.19 | 8.12 | |||
| Women | First Q, 9.5 ng/mL | 9.5 | 16 | 14 | 30 | 1 | ||||
| Second Q, 13.5 ng/mL | 13.5 | 22 | 14 | 36 | 0.89 | 0.26 | 3.1 | |||
| Third Q, 18.4 ng/mL | 18.4 | 8 | 14 | 22 | 0.54 | 0.13 | 2.16 | |||
| Fourth Q, 25.4 ng/mL | 25.4 | 9 | 13 | 22 | 0.22 | 0.04 | 1.15 | |||
| Hong | All | First Q, <14.3 ng/mL | 10.1 | 31 | 42 | 73 | 1 | Age, sex, BMI, smoking, alcohol drinking, physical activity, corrected calcium level | ||
| Second Q, 14.3–18.5 ng/mL | 16.4 | 29 | 42 | 71 | 0.87 | 0.43 | 1.74 | |||
| Third Q, 18.6–23.8 ng/mL | 21.2 | 41 | 31 | 72 | 0.4 | 0.2 | 0.82 | |||
| Fourth Q, ≥23.9 ng/mL | 29.1 | 42 | 28 | 70 | 0.38 | 0.18 | 0.8 | |||
| Otani | Men | First Q, <22.9 ng/mL | 18.3 | 43 | 74 | 117 | 1 | Age, sex, BMI, smoking, alcohol consumption, physical exercise, vitamin supplement use, family history of colorectal cancer, total energy intake, dietary fibre intake, folate intake, calcium intake, vitamin D intake, n-3 fatty acid intake, red meat intake, fish intake | ||
| Second Q, 22.9–27.5 ng/mL | 25.2 | 40 | 85 | 125 | 0.76 | 0.42 | 1.4 | |||
| Third Q, 27.6–32.0 ng/mL | 29.8 | 36 | 85 | 121 | 0.76 | 0.39 | 1.5 | |||
| Fourth Q, >32.1 ng/mL | 36.5 | 44 | 80 | 124 | 0.73 | 0.35 | 1.5 | |||
| Women | First Q, <18.7 ng/mL | 15.2 | 41 | 77 | 118 | 1 | ||||
| Second Q, 18.7–22.2 ng/mL | 20.5 | 34 | 73 | 107 | 1 | 0.55 | 1.9 | |||
| Third Q, 22.3–26.9 ng/mL | 24.6 | 44 | 71 | 115 | 1.2 | 0.65 | 2.3 | |||
| Fourth Q, >27.0 ng/mL | 31.6 | 41 | 76 | 117 | 1.1 | 0.5 | 2.3 | |||
| Takahashi | Men | First Q, <22 ng/mL | 20 | 128 | 142 | 270 | 1 | BMI, hospital, rank in the self-defence forces, smoking, alcohol drinking, parental history of colorectal cancer, physical activity, type of blood sample, the month of blood drawing | ||
| Second Q, 23–25 ng/mL | 24 | 162 | 156 | 318 | 1.21 | 0.86 | 1.7 | |||
| Third Q, 26–29 ng/mL | 27.5 | 223 | 208 | 431 | 1.21 | 0.87 | 1.69 | |||
| Fourth Q, >30 ng/mL | 33 | 143 | 142 | 285 | 1.25 | 0.85 | 1.84 | |||
| Yamaji | All | First Q, 14–19 ng/mL | 16.5 | 145 | 129 | 274 | 1 | Age, sex, BMI, screening periods, the season of blood collection, smoking, alcohol drinking, family history of colorectal cancer, non-steroidal anti-inflammatory drug use, height, daily energy intake | ||
| Second Q, 20–23 ng/mL | 21.5 | 132 | 128 | 260 | 0.86 | 0.6 | 1.24 | |||
| Third Q, 24–26 ng/mL | 25 | 157 | 145 | 302 | 0.91 | 0.64 | 1.29 | |||
| Fourth Q, 27–31 ng/mL | 29 | 175 | 144 | 319 | 1.03 | 0.73 | 1.46 | |||
| Fifth Q, 31–34 ng/mL | 32.5 | 128 | 157 | 285 | 0.64 | 0.45 | 0.92 | |||
| Ying | All | First Q, <7.29 ng/mL | 3.65 | 80 | 53 | 133 | 1 | Age, sex, BMI, smoking, drinking, history of diabetes, hypertension, vitamin D binding protein | ||
| Second Q, 7.29–14.61 ng/mL | 10.95 | 49 | 53 | 102 | 0.62 | 0.35 | 1.12 | |||
| Third Q, 14.61–28.84 ng/mL | 21.73 | 46 | 53 | 99 | 0.67 | 0.38 | 1.20 | |||
| Fourth Q, ≥28.84 ng/mL | 35.96 | 37 | 53 | 90 | 0.53 | 0.29 | 0.98 | |||
| Yurekli | All | First Q, <8.6 ng/mL | 7.1 | 24 | 48 | 72 | 1 | Age, sex, BMI, smoking, alcohol intake | ||
| Second Q, 8.6–10.1 ng/mL | 9.35 | 20 | 53 | 73 | 0.48 | 0.24 | 0.98 | |||
| Third Q, 10.1–14.5 ng/mL | 12.3 | 25 | 48 | 73 | 0.51 | 0.25 | 1.03 | |||
| Fourth Q, ≥14.5 ng/mL | 18.9 | 27 | 46 | 73 | 0.69 | 0.36 | 1.36 |
All*: all participants, including men and women
BMI, body mass index; LCI, 95% CI’s lower CI; OR, Odds Ratio; UCI, 95% CI’s upper CI.